LY6E

Across TCGA pan-cancer cohorts, LY6E mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LY6E data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LY6E mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LY6E expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where LY6E mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.738	0.991	.001	47	view →
HNSC	DFS	Median	All	0.860	0.361	.022	10	view →
LUAD	DFS	Median	II,III,IV	0.772	0.944	.032	6	view →
PDAC	DFS	Quartile	II,III,IV	0.360	0.704	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LY6E–CCRCC (OS)

Open the CCRCC breakdown →